Results 51 to 60 of about 3,560 (171)

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Journal of Blood Medicine, 2016
Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, 2Division of Hematology, University of Washington, Seattle, WA, USA Abstract: Inhibition of platelet production and mediated by ...
Vishnu P, Aboulafia DM
doaj  

Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies

JGH Open
Thrombocytopenia and leukopenia are among the most common hematological abnormalities in patients with chronic liver disease (CLD), particularly among those with cirrhosis.
Xiaoxiao Wang, Shuyan Fu, Xiaohong Zhu, Yanping Zhao   +3 more
doaj   +1 more source

Immune thrombocytopaenia in children and adolescents – current management and Polish perspective

Pediatria Polska
Immune thrombocytopaenia (ITP) is the most common cause of acquired thrombocytopaenia diagnosed in paediatric patients. It is described as an isolated thrombocytopaenia without other factors, which may cause a decrease in platelets.
Marta Andrzejewska, Ewelina Truszkowska, Katarzyna Derwich   +2 more
doaj   +1 more source

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Pediatric Health, Medicine and Therapeutics, 2016
Michele P Lambert,1,2 1Division of Hematology, The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Pediatric data on the use of thrombopoietin ...
Lambert MP
doaj  

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Clinical Case Reports, 2017
Key Clinical Message Thrombopoietin receptor agonists (TPO‐RAs) are used as effective alternative treatments in ITP patients unresponsive to first‐/second‐line therapies.
Cristina Santoro, Paola Volpicelli, Erminia Baldacci, Grazia Ferrara, Alice Di Rocco, Antonietta Ferretti, Marika Porrazzo, Maria Gabriella Mazzucconi   +7 more
doaj   +1 more source

Thrombocytopenia in Pregnancy: A 5‐Year Analysis of Characteristics and Practices From a Tertiary Academic Center

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

Interstitial 11q Deletions and Terminal 11q Duplications Cause a Bleeding Tendency due to Platelet Dysfunction That Is Similar to 11q Deletions Causing Jacobsen Syndrome

European Journal of Haematology, Volume 117, Issue 3, Page 662-672, September 2026.
ABSTRACT Introduction Jacobsen syndrome, resulting from a terminal deletion of chromosome 11 (11q), may lead to an increased bleeding tendency due to low platelet counts or platelet dysfunction. Currently, information on bleeding tendency and platelet function in patients with nonterminal 11q‐aberrations such as larger deletions, interstitial 11q ...
Elise J. Huisman, Virgil A. S. H. Dalm, Marieke Joosten, Frans J. Smiers, Leendert Porcelijn, Arjan Hoogendijk, Hans Janssen, Nicole N. van der Wel, Idske C. L. Kremer Hovinga, Masja de Haas, Marjon H. Cnossen   +10 more
wiley   +1 more source

Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature

Case Reports in Oncology, 2020
Immune thrombocytopenia (ITP) is a rare paraneoplastic syndrome of solid tumor malignancies. In previously described cases of renal cell carcinoma (RCC) associated with secondary ITP, treatment has consisted of nephrectomy, splenectomy, and ...
Dillon C. Cockrell, Raj S. Kasthuri, Ersan Altun, Tracy L. Rose, Matthew I. Milowsky   +4 more
doaj   +1 more source